Literature DB >> 18808400

Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial.

E Lauterbach1, W Felber, B Müller-Oerlinghausen, B Ahrens, T Bronisch, T Meyer, B Kilb, U Lewitzka, B Hawellek, A Quante, K Richter, A Broocks, F Hohagen.   

Abstract

OBJECTIVE: Evidence based on controlled studies is still limited for treatment strategies that prevent recurrence of suicide attempts. Findings from observational as well as meta-analytic studies strongly suggest that lithium may have suicide-protective properties.
METHOD: Patients with a recent suicide attempt in the context of an affective spectrum disorder (n = 167) were treated with either lithium or placebo during a 12-month period.
RESULTS: Survival analysis showed no significant difference of suicidal acts between lithium and placebo-treated individuals (adjusted hazard ratio 0.517; 95% CI 0.18-1.43). However, post hoc analysis revealed that all completed suicides had occurred in the placebo group accounting for a significant difference in incidence rates (P = 0.049).
CONCLUSION: Results indicate that lithium treatment might be effective in reducing the risk of completed suicide in adult patients with affective disorders. Our findings contribute to the growing body of evidence suggesting a specific antisuicidal effect of lithium.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18808400     DOI: 10.1111/j.1600-0447.2008.01266.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  30 in total

1.  Discontinuation of lithium because of side effects.

Authors:  Tomas Hajek; Martin Alda; Paul Grof
Journal:  J Psychiatry Neurosci       Date:  2011-11       Impact factor: 6.186

2.  The ultimate endpoint.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2012-02-06       Impact factor: 53.440

Review 3.  [Anti-suicidal effect of lithium: current state of research and its clinical implications for the long-term treatment of affective disorders].

Authors:  U Lewitzka; M Bauer; W Felber; B Müller-Oerlinghausen
Journal:  Nervenarzt       Date:  2013-03       Impact factor: 1.214

4.  Existing and novel biological therapeutics in suicide prevention.

Authors:  Joshua J Griffiths; Carlos A Zarate; J J Rasimas
Journal:  Am J Prev Med       Date:  2014-09       Impact factor: 5.043

5.  [No high-level evidence for the suicide prevention through antidepressants or clozapine].

Authors:  C Baethge
Journal:  Nervenarzt       Date:  2017-03       Impact factor: 1.214

6.  Suicidality in Childhood and Adolescence.

Authors:  Merle Becker; Christoph U Correll
Journal:  Dtsch Arztebl Int       Date:  2020-04-10       Impact factor: 5.594

7.  Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.

Authors:  Rachael W Taylor; Lindsey Marwood; Emanuella Oprea; Valeria DeAngel; Sarah Mather; Beatrice Valentini; Roland Zahn; Allan H Young; Anthony J Cleare
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

Review 8.  [Psychopharmaceuticals for treatment of suicidal patients and for suicide prevention].

Authors:  R Haußmann; M Bauer; U Lewitzka; B Müller-Oerlinghausen
Journal:  Nervenarzt       Date:  2016-05       Impact factor: 1.214

Review 9.  [Side effects and risk profile of lithium: critical assessment of a systematic review and meta-analysis].

Authors:  T Bschor; M Bauer
Journal:  Nervenarzt       Date:  2013-07       Impact factor: 1.214

10.  NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER.

Authors:  Daniel C Mathews; Erica M Richards; Mark J Niciu; Dawn F Ionescu; Joseph J Rasimas; Carlos A Zarate
Journal:  Transl Neurosci       Date:  2013-06       Impact factor: 1.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.